Skip to main content
. Author manuscript; available in PMC: 2014 Apr 30.
Published in final edited form as: Cell Mol Immunol. 2013 Sep 30;11(1):71–78. doi: 10.1038/cmi.2013.43

Figure 4.

Figure 4

AAV/HBV-infected mice respond to HBsAg vaccination with CpG. (a) C57BL/6 mice were infected with AAV/HBV (2×1010 vg) and were subsequently immunized with HBsAg plus CpG (50 or 1 μg per mouse) at 3 weeks post-infection (wpi) followed by a boost with Engerix-B (2 μg/mouse) at 7 wpi. Serum HBsAg levels in the different groups were monitored by ELISA (n=3). (b) HBsAb titers were measured by ELISA. (c) The ALT in immunized mice was monitored at different time points post-vaccination. (d) AAV/HBV (2×1010 vg)-infected mice were treated with HBsAg plus two respective doses of CpG (50 or 1 μg per mouse) or high-dose CpG alone at 3 wpi. ENV190-specific CD8+ T cells in the liver were detected by IFN-γ ELISPOT at 10 days post-vaccination (n=5). AAV, adeno-associated virus; ALT, alanine aminotransferase; HBsAg, HBV surface antigen; HBV, hepatitis B virus.